Financial Health Snapshot
What does DaVita’s latest financial snapshot show in Q1 2026?
Mixed. The strongest factor is $140M in free cash flow, which still gives DaVita room to fund operations, while the main concern is the $1063B debt principal and material interest cost pressure.
For Q1 2026, the verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. DaVita’s recurring dialysis base supports cash flow, but weaker top-line momentum and higher financing burden keep the profile under pressure. Exploring DaVita Inc. (DVA) Investor Profile: Who's Buying and Why?
Operating Income: $482M in Q1 2026, with -1257% growth versus the comparable period, and Free Cash Flow growth was -4465%; the first metric to analyze deeper is total debt principal because it frames liquidity, refinancing risk, and capital allocation.
Revenue Quality
Does DaVita’s revenue growth produce quality earnings?
Mixed. DaVita’s revenue is supported by a recurring per-treatment reimbursement model and pricing, but the clearest divergence is weak organic volume growth in Q1 2026, where normalized non-acquired US treatment volume rose only 0.1% year over year.
Revenue quantity is holding up, but quality is less clean because price and mix are doing more work than volume. Investors compare durable revenue with operating income, net income, and EPS across the same annual or quarterly periods to see whether growth turns into real profit, not just sales. For more context on DaVita Inc., see Mission Statement, Vision, & Core Values (2026) of DaVita Inc. (DVA).
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $13.643B, FY2025 consolidated revenue | Previous comparable revenue not provided | Recurring reimbursement model; Q1 2026 organic volume growth was 0.1%, while Q4 2025 Revenue per Treatment was $422.60, up 8% year over year | Growth looks repeatable on reimbursement and pricing, but volume expansion is limited |
| Operating Income | US Dialysis Operating Income was $506M in Q1 2026 | Previous comparable value not provided | Growth was slower and weaker than revenue quality signals | Operating leverage looks modest, so revenue growth is not clearly translating into stronger operating profit |
| Net Income | Net Income Growth: -1566% in Q1 2026 | Previous comparable value not provided | Operating, interest, tax, or unusual-item effects not fully provided | Final earnings do not confirm the revenue trend |
| Diluted EPS | EPS Diluted Growth: 1714% in Q1 2026 | Previous comparable diluted EPS not provided | Weighted Average Shares Diluted Growth was -2182% | Per-share results improved faster than net income because fewer shares boosted EPS |
How durable is DaVita’s revenue?
The strongest durability signal is recurring dialysis reimbursement across Medicare and commercial insurers. The biggest visibility limit is that Q1 2026 normalized non-acquired US treatment volume growth was only 0.1%, so pricing matters more than patient volume.
- Demand Quality: Recurring treatment demand gives high visibility, but volume growth is still modest and tied to chronic care utilization.
- Pricing and Volume: Revenue per Treatment was $422.60 in Q4 2025, up 8% year over year; the volume split was not fully provided beyond 0.1% growth.
- Diversification: US Dialysis Revenue was $2.942B in Q1 2026 and Ancillary Services Revenue was $498M, but the business remains concentrated in dialysis.
That mix supports cash generation, but profitability still depends on cost control and conversion from revenue to earnings.
Profitability and Cash Flow
Can DaVita convert operating profit into dependable free cash flow?
Not consistently in Q1 2026. DaVita posted $107B gross profit, $48189M operating income, and $19753M net income, but operating cash flow growth of -4067% and free cash flow growth of -4465% show weak cash conversion despite annual FY2025 free cash flow of $1024B.
Operating profit and cash flow are not the same thing. Gross margin shows treatment economics, operating margin shows clinic-level efficiency, and net margin reflects interest and taxes. For DaVita, cash conversion matters more than accounting profit because interest expense of $14513M and income tax expense of $6620M sit between operating income and net income. See the Mission Statement, Vision, & Core Values (2026) of DaVita Inc. (DVA) for how the company frames its operating priorities.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable in supplied data | Unavailable in supplied data | Revenue per treatment was $42260, up 8% year-over-year, while patient care cost per treatment was $27960, up $15 year-over-year from pharmacy, wage, and supply inflation. | Unit economics remain supported by pricing, but cost inflation limits spread improvement. |
| Operating Margin | Unavailable in supplied data | Unavailable in supplied data | Operating income was $48189M in Q1 2026, but the supplied data does not give a compatible margin percentage. | Profitability is positive, yet scale alone does not prove operating efficiency. |
| Net Margin | Unavailable in supplied data | Unavailable in supplied data | Net income was $19753M in Q1 2026 after $14513M of interest expense and $6620M of income tax expense. | Final profit is lower than operating profit because financing and tax costs absorb earnings. |
| Operating Cash Flow | Q1 2026: growth -4067% | Previous comparable value not supplied | Direction diverged from net income, and no working-capital detail was supplied. | Reported earnings did not convert cleanly into operating cash in the latest quarter. |
| Free Cash Flow | Q1 2026: $140M | FY2025: $1024B | Capital expenditure data was not supplied, so the reinvestment burden cannot be isolated here. | Cash remaining after investment is hard to judge from the supplied data, even though FY2025 cash generation was positive. |
What most affects DaVita's cash conversion?
Patient care cost inflation is the clearest driver. Revenue per treatment rose faster than costs, but pharmacy, wage, and supply pressure still makes cash conversion look temporary and fragile rather than fully structural.
- Main Driver: Rising patient care costs are squeezing cash conversion, even with better revenue per treatment. That looks partly structural if inflation persists.
- Evidence Gap: The supplied data does not show working-capital changes or capital expenditure, so true free cash flow quality is incomplete.
- Metric to Monitor: Watch revenue per treatment versus patient care cost per treatment, plus operating cash flow growth.
Debt Load
Can DaVita’s balance sheet support its obligations and investment needs?
DaVita’s balance sheet is Mixed. The main protection is ongoing debt-market access and cash generation, while the main concern is meaningful leverage, which leaves less room if operating cash flow weakens.
Cash alone does not tell the full story. For DaVita, the key tests are working capital, asset quality, debt service, solvency, liquidity, and refinancing access together, because a company can have usable cash and still face pressure if debt maturities, interest costs, or collateral needs tighten.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | $72640M cash and cash equivalents versus $1322B total debt as of 2026-03-31. | Mixed | Near-term obligations look manageable, but cash does not fully offset the scale of debt. |
| Total and Net Debt | $1063B total debt principal at March 31, 2026; weighting average effective interest rate of 544%. | Mixed | Leverage is meaningful and limits flexibility, even with a cash balance on hand. |
| Debt Service and Refinancing | February 02, 2026 refinancing of Term Loan B-1 and issuance of 675% senior notes due 2033; $207M of outstanding letters of credit under a bilateral secured facility as of May 05, 2026. | Mixed | Recent refinancing shows debt-market access, which reduces near-term funding uncertainty if cash flow stays stable. |
| Asset Quality | No verified receivable, inventory, goodwill, intangibles, or impairment data is provided here. | Mixed | Asset-quality risk cannot be fully assessed from the supplied data, so investors should watch for changes in balance-sheet composition. |
| Liabilities and Equity | No verified total liabilities or shareholders' equity figure is provided here. | Mixed | The capital base cannot be measured precisely from the supplied figures, so solvency should be judged with cash flow and refinancing access. |
Which balance-sheet risk matters most for DaVita?
Refinancing risk matters most, followed by leverage. DaVita has shown debt-market access, but the large principal balance means future funding costs and cash generation still deserve close monitoring.
- Current Exposure: $1063B total debt principal and $207M in letters of credit as of May 05, 2026.
- Protection: The February 02, 2026 refinancing and 675% senior notes due 2033 show access to funding.
- Warning Signal: Watch whether cash generation stays stable enough to support debt service and future refinancing.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. Exploring DaVita Inc. (DVA) Investor Profile: Who's Buying and Why?
Capital Efficiency
Is DaVita using cash flow in ways that strengthen returns?
Capital efficiency looks Mixed, because DaVita is generating enough cash to fund buybacks and strategic investment, but leverage still limits how far that cash can be pushed. Internal cash appears sufficient for current reinvestment needs, though not without keeping debt capacity in view.
Return quality should be judged alongside leverage, dialysis asset intensity, capital expenditure, working capital needs, and any outside funding. DaVita also needs to balance shareholder returns with operational reinvestment and strategic moves such as the pending minority stake in Elara Caring for approximately $200M. For mission context, see Mission Statement, Vision, & Core Values (2026) of DaVita Inc. (DVA).
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | No verified ROIC value was supplied for DaVita. | Without a ratio, the main check is whether cash generation and operating discipline appear strong enough to support capital spending. | Investors can still judge whether invested capital seems to create operating value by looking at cash flow, buybacks, and strategic spending. |
| ROE and ROA | No verified ROE or ROA values were supplied. | Leverage can lift ROE, while DaVita’s asset-heavy model can pressure ROA if assets do not earn enough cash return. | Shareholder return quality depends on business economics, not just leverage. |
| Maintenance and Growth Investment | FY2025 Free Cash Flow was $1.024B. Home dialysis adoption reached 15% of patients in 2025, and DaVita has a strategic investment in Elara Caring for approximately $200M. | The evidence supports ongoing reinvestment, but the home dialysis shift and strategic investment suggest capital is also being used to support future growth. | Capital appears adequate for sustaining operations and selective growth, but it still has to be weighed against debt load. |
| Internal Funding Capacity | DaVita repurchased 127M shares for $1.79B at an average price of $140.09 during the full year 2025. In Q1 2026, it repurchased 3.0M shares for $403M at an average price of $133.70 from April 01, 2026 to May 05, 2026, and an additional 2.0M shares for $302M at an average price of $149.81. About 642M common shares were outstanding as of May 05, 2026. | The buybacks show strong internal funding, but they only strengthen per-share returns if they do not weaken debt capacity. | DaVita is funding returns largely from internal cash, which supports flexibility as long as leverage stays manageable. |
Are DaVita's returns on capital sustainable?
They look sustainable if operating cash flow keeps funding repurchases and strategic investment without stretching leverage too far. The main risk is that debt pressure could weaken returns if buybacks or expansion outrun cash generation.
- Operating Source: Cash generation and asset use, supported by 15% home dialysis adoption.
- Funding Requirement: Share repurchases and the approximately $200M Elara Caring investment.
- Durability Test: Returns weaken if buybacks continue while debt capacity tightens or free cash flow stops covering reinvestment.
Financial resilience
How resilient is DaVita and which warning signs matter most?
Resilience looks Mixed. The main buffer is DaVita’s reimbursement support, including the 22% Medicare base reimbursement rate increase for 2026 to $281.71 per treatment, but the most important verified warning sign is rising patient care cost inflation.
DaVita can still protect liquidity and debt service if reimbursement holds, but resilience gets weaker if patient care costs keep rising faster than revenue per treatment. The company also has support from home dialysis, value-based care, refinancing, and more than $5B in medical costs managed under value-based arrangements. Its Mission Statement, Vision, & Core Values (2026) of DaVita Inc. (DVA) also matter because they shape how management balances care quality and capital use.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Q4 2025 Patient Care Cost per Treatment of $279.60 rose $15 year over year, which can squeeze operating leverage, cash flow, and debt capacity if reimbursement does not keep pace. | Medicare reimbursement support and the 22% 2026 rate increase help offset some cost pressure. | Watch for patient care cost per treatment rising faster than revenue per treatment. |
| Working-Capital or Investment Pressure | Higher pharmacy, wage, and supply inflation can absorb operating cash and limit room for investment in home dialysis, value-based care, and other growth areas. | More than $5B in medical costs managed under value-based arrangements and internal operating cash help support ongoing spending. | Monitor whether operating cash flow weakens or investment spending starts to outpace cash generation. |
| Interest or Refinancing Pressure | Refinancing costs or tighter credit could reduce free cash flow and narrow flexibility for debt service and maturities. | Visible debt-market access and refinancing activity provide a financing backstop when markets stay open. | Watch for higher borrowing costs, tighter refinancing terms, or weaker liquidity access. |
Which financial warning signs should investors monitor at DaVita?
Top signals are patient care cost inflation, realized revenue per treatment, and any slowdown in operating cash flow. Cost inflation is the confirmed pressure; GLP-1-related volume delay is a future risk, not yet a current deterioration signal.
Patient care cost inflation
Q4 2025 Patient Care Cost per Treatment of $279.60 was up $15 year over year, driven by pharmacy, wage, and supply inflation. The next metric is patient care cost per treatment versus revenue per treatment.
Reimbursement mismatch
CMS finalized a 22% increase in the Medicare base reimbursement rate for 2026, to $281.71 per treatment. That helps, but investors should watch realized revenue per treatment to see whether the benefit fully offsets cost pressure.
GLP-1 volume uncertainty
GLP-1 data showed possible benefits, including a 17% reduction in mortality for dialysis patients using GLP-1s and a 9% reduction in hospitalization for in-center hemodialysis patients, but long-term adoption could delay Stage 4 CKD entry into ESRD by 5 to 10 years.
Financial Health Scorecard
What does DaVita’s financial health mean for investors?
DaVita earns a Mixed score. The strongest factor is recurring free cash flow, while the weakest factor is leverage. The most important condition for the investment case is whether cash generation stays strong enough to manage debt and cost pressure; its operating discipline ties back to Mission Statement, Vision, & Core Values (2026) of DaVita Inc. (DVA).
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Recurring dialysis demand and Q4 2025 Revenue per Treatment of $42260 support durability, but Q1 2026 Revenue Growth was -564% and normalized non-acquired US treatment volume growth was 01%. |
| Profitability and Cash | Strong | FY2025 Free Cash Flow was $1024B and Q1 2026 Free Cash Flow was $140M, showing solid cash conversion even with cost pressure. |
| Balance Sheet and Liquidity | Mixed | Total Debt Principal was $1063B and Weighted Average Effective Interest Rate was 544%, but refinancing actions and 675% senior notes due 2033 show funding access. |
| Capital Efficiency | Mixed | Buybacks are supported by cash generation, but leverage limits flexibility and keeps more capital tied to debt service than growth reinvestment. |
| Financial Resilience | Mixed | Reimbursement, wage, supply, and GLP-1 volume risks remain, but home dialysis, value-based care, and refinancing improve resilience. |
- What Supports the Thesis: Dependable recurring cash generation with strong free cash flow despite ongoing operating pressure.
- What Challenges the Thesis: High debt and cost pressure reduce flexibility and raise refinancing sensitivity.
- What to Monitor: Free Cash Flow, Total Debt Principal, normalized non-acquired US treatment volume growth.
Forecasts and scenarios should focus on whether stable cash flow can offset leverage and margin pressure, since that balance will drive DaVita’s valuation range.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much cash flow supports DaVita buybacks?
FY2025 Free Cash Flow was $1024B, and Q1 2026 Free Cash Flow was $140M DaVita also repurchased 127M shares for $179B in 2025 and 30M shares for $403M in Q1 2026, so buybacks should be assessed against debt capacity
Why does revenue per treatment matter financially?
Revenue per treatment shows how much DaVita earns from each dialysis treatment before patient care costs and overhead Q4 2025 Revenue per Treatment was $42260, up 8% year-over-year, helping offset cost inflation and supporting earnings quality
What keeps DaVita refinancing risk manageable?
DaVita refinanced its Term Loan B-1 and issued 675% senior notes due 2033 That does not remove leverage risk, but it shows debt-market access and gives investors a clearer view of funding capacity alongside Total Debt Principal of $1063B
How could nursing costs pressure DaVita margins?
Higher nursing wages can raise patient care cost per treatment and reduce the benefit from pricing gains Q4 2025 Patient Care Cost per Treatment was $27960, up $15 year-over-year due to pharmacy, wage, and supply inflation
Do share repurchases improve DaVita returns?
Repurchases can improve per-share results when cash flow is strong and debt remains manageable DaVita’s Q1 2026 EPS Diluted Growth was 1714% while Weighted Average Shares Diluted Growth was -2182%, but leverage means funding discipline remains important